Evidence map›Paper›PMID 38511126›Full record

ArticleCritical care explorations2024

Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study.

John Muscedere, David M Maslove, Christopher J Barden, Donald F Weaver, J Gordon Boyd, Stephanie Sibley, Tracy Boyd, Oleksa Rewa, Martin Albert, Marios Roussos and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care explorations, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

John MuscedereDepartment of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
David M MasloveDepartment of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
Christopher J BardenKrembil Research Institute, University Health Network, Toronto, ON, Canada.
Donald F WeaverKrembil Research Institute, University Health Network, Toronto, ON, Canada.
J Gordon BoydDepartment of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
Stephanie SibleyDepartment of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
Tracy BoydDepartment of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
Oleksa RewaDepartment of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada.
Martin AlbertDivision of Critical Care, Department of Medicine, Hôpital du Sacré-Coeur Research Center, Université de Montréal, Montreal, QC, Canada.
Marios RoussosDepartment of Medicine, Division of Critical Care, Hôpital Cité-de-la-Santé, Laval, QC, Canada.
Patrick A NormanKingston Health Sciences Centre, Kingston, ON, Canada.
Andrew G DayKingston Health Sciences Centre, Kingston, ON, Canada.
Kingston Health Sciences Centre · CAQueen's University · CAKrembil Research InstituteUniversity Health Network · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesRespiratory failure secondary to COVID-19 is associated with morbidity and mortality. Current anti-inflammatory therapies are effective but are given systemically and have significant side effects. Furosemide has anti-inflammatory properties, can be administered by inhalation, and is inexpensive. We investigated the efficacy of nebulized furosemide as an adjunctive therapy for COVID-19 respiratory failure.

designA double-blind, randomized, placebo-controlled trial.

settingMulticenter ICU study. PATIENTS: Adults requiring invasive mechanical ventilation secondary to COVID-19.

interventionPatients were randomized within 48 hours of intubation to receive inhaled furosemide or placebo until day 28, death, or liberation from mechanical ventilation. MEASUREMENTS AND MAIN

resultsThe study was stopped early due to waning incidence of COVID-19; 39 patients were available for analysis with mean ± sd age of 70.5 (10.8) years, Acute Physiology and Chronic Health Evaluation II 26.1 (7.8) and Fio

conclusionsIn this trial of inhaled furosemide for COVID-19 respiratory failure, differences in Pao

Indexed as

artificialCOVID-19furosemidehumansinflammationpneumoniarespiration

Identifiers

PMID38511126
PMCPMC10954058
OpenAlexW4391530532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.